Reduced Intensity Conditioning

Phase 2

Reduced Intensity Conditioning is one of 2 therapeutic programs targeting Primary T-cell Immunodeficiency Disorders. It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[2][1]

Indication

Primary T-Cell Immunodeficiency DisordersRecruiting

Primary T-Cell Immunodeficiency DisordersPhase 2

Recruiting

Competition

Competitive Landscape

3 competitors in Primary T-Cell Immunodeficiency Disorders

#DrugCompanyPhaseTrials

GVHD Prophylaxis

NNational Cancer Institute (NCI)

Phase 2

1 2

Reduced Intensity Conditioning

NNational Cancer Institute (NCI)

Phase 2

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2036

Phase 2Recruiting

Primary T-Cell Immunodeficiency Disorders

NCT02579967

Clinical

Trials by Indication[1]

Primary T-cell Immunodeficiency Disorders1 trial

Pilot Trial of Allogeneic Blood or Marrow Transplantation for Primary Immunodeficiencies

Recruiting·NNational Cancer Institute (NCI)·Phase 2·NCT02579967·354 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for Reduced Intensity Conditioning. U.S. National Library of Medicine, National Institutes of Health.
[2]
Open Targets Platform — Drug–disease associations for Reduced Intensity Conditioning. EMBL-EBI & Wellcome Sanger Institute.
[3]
SEC EDGAR — National Cancer Institute (NCI) company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Highest Phase: Phase 2[1]
Company: NNational Cancer Institute (NCI)

Reduced Intensity Conditioning

Status by Indication[2][1]

Competitive Landscape

Expected Milestones

Q4 2036

Trials by Indication[1]

Primary T-cell Immunodeficiency Disorders1 trial

References

Drug Info

Quick Facts

Related News